Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Philadelphia, US
173 (est)

Adaptimmune Locations

Philadelphia, US
Milton, GB

Adaptimmune Metrics

Adaptimmune Summary

Founding Date


Market capitalization

$367 M

Closing share price


Adaptimmune Market Value History

Adaptimmune News

Adaptimmune Company Life